This is a paid advertisement for SmartBrief readers.
The content does not necessarily reflect the view of SmartBrief or its Association partners.
You are cordially invited to attend a REZZAYO™ (rezafungin for injection) virtual program
Entitled
Once-Weekly REZZAYO™ (rezafungin for injection): A next generation echinocandin
Presented by Jose Vazquez, MD, FACP, FIDSA Medical College of Georgia/Augusta University North Augusta, SC
On Wednesday, July 23, 2025 at 12:00 PM ET
Location A weblink will be provided upon registration. This is a Virtual (web based) program. The speaker will be presenting remotely and available for questions.
Space is Limited. Preferred to RSVP by: 4 calendar days prior to the program date listed above
This program is not eligible for CME/CE Credits. As a healthcare professional, certain laws or policies applicable to you may prohibit or limit meals or items of value you may receive. We ask that you comply with any restrictions that govern your receipt of meals or items of value. By accepting food and/or refreshments at this program, you represent that neither your employer, nor the state(s) in which you are licensed, impose restrictions that preclude you from accepting these items. Accepting a meal involves a reportable transfer of value from Melinta to you. The amount of that value will be reported as required by law in accordance with Melinta policy. Melinta does not provide or pay for alcohol at its programs. Attendance at this educational program is limited to healthcare professionals only. Thank you for your cooperation.
INDICATION AND USAGE REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.
Limitations of Use REZZAYO™ has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.
IMPORTANT SAFETY INFORMATION Contraindications REZZAYO™ is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.
Warnings and Precautions
Infusion-related Reactions: REZZAYO™ may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion.
Photosensitivity: REZZAYO™ may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation.
Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO™. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO™ therapy.
Adverse Reactions Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.
Please see Full Prescribing Information for REZZAYO™ at www.rezzayo.com
About this email: SmartBrief will occasionally
send emails from our business partners promoting products and services likely to
be of interest to our readers. The content of these messages does not necessarily reflect
the view of SmartBrief or its association partners.
